Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections
Renee Ackley, Danya Roshdy, J. Wayne Meredith, Sarah Minor, William E. Anderson, Gerald A. Capraro, Christopher Polk
Abstract
< 0.01). No difference in 30- and 90-day mortality resulted, and rates of AE were similar between groups. In patients with recurrent infection, development of resistance occurred in three patients that received ceftazidime-avibactam monotherapy and in no patients in the meropenem-vaborbactam arm. Clinical success was similar between patients receiving ceftazidime-avibactam and meropenem-vaborbactam for treatment of CRE infections, despite ceftazidime-avibactam being used more often as a combination therapy. Development of resistance was more common with ceftazidime-avibactam monotherapy.
Topics & Concepts
Ceftazidime/avibactamCarbapenem-resistant enterobacteriaceaeMedicineMeropenemEnterobacteriaceaeCeftazidimeCarbapenemAvibactamAntibioticsRetrospective cohort studyEnterobacteriaceae InfectionsMicrobiologyInternal medicineIntensive care medicineBiologyPseudomonas aeruginosaAntibiotic resistanceEscherichia coliBacteriaGeneticsBiochemistryGeneAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyUrinary Tract Infections Management